{'fraction_non_alphanumeric': 0.03469210754553339, 'fraction_numerical': 0.004336513443191674, 'mean_word_length': 5.748538011695906, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Psychopharmacology in Medical Illnesses

A variety of medical illnesses can cause psychiatric symptoms, most commonly depression, anxiety, manic states, and delusions or hallucinations, in that order. Before DSM-III in 1980, psychiatric symptoms caused by medical illnesses were classified as organic mental disorders. DSM-III changed the term “organic” to “secondary to a medical illness.” In DSM-5, mania and depression secondary or due to a medical illness were moved to “other mental disorders.” These days the terms “organic,” “secondary,” and “neuropsychiatric” are used interchangeably. Psychotropic agents mainly have symptomatic effects when used for mood or anxiety or cognitive symptoms in the context of medical illnesses. In chronic traumatic encephalopathy, low-dose lithium may assist with mood and impulsivity and suicidality, as well as potential dementia progression. In a range of neurological illnesses, symptomatic psychotropic treatments have limited value. In cardiovascular disease, monoamine agonists are limited in depressive benefit, have little definable cardiovascular benefit, and have some evidence of cardiovascular harm.